Navigation Links
Life Technologies Announces First Quarter 2011 Results

CARLSBAD, Calif., April 26, 2011 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced results for its first quarter ending March 31, 2011. Non-GAAP revenue for the first quarter was $897 million, an increase of 1 percent over the $887 million reported for the first quarter of 2010. Organic revenue growth for the quarter was flat compared to the same period prior year, due to the impact of difficult year over year comparables and the extraordinary events that occurred in Japan. Excluding these items, organic growth for the quarter was 5 percent.


"Our ability to drive performance is a direct result of our commitment to innovation and operational excellence," said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies. "We continue to invest in important new products and emerging markets while working to become ever more efficient in our operations.  We have laid the groundwork to accelerate both revenue and earnings in the remainder of the year and we are on track to meet our full year financial goals."

Analysis of First Quarter 2011 ResultsFirst quarter non-GAAP 2011 revenue increased
percent over the previous year.  Revenue growth without the impact from currency, completed acquisitions and divestitures was flat.  

  • Foreign currency exchange had a negative 1 point impact and prior acquisitions and divestitures contributed approximately 2 points to reported revenue growth.
  • Non-GAAP gross margin in the first quarter was 66.3 percent, 200 basis points lower than the same period prior year due to the negative impact from currency and mix partially offset by the positive impact of price.
  • Non-GAAP operating margin was 28.2 percent in the first quarter, 130 basis points lower than the same period prior year due to lower gross margins, partially offset by lower operating expenses.
  • First quarter non-GAAP tax rate was 27.6 percent.
  • Diluted weighted shares outstanding were 186 million in the first quarter. During the quarter we repurchased approximately 4.4 million shares at an average price of $53.71 per share.
  • Cash flow from operating activities for the first quarter was $115 million.  First quarter capital expenditures were $17 million and resulting free cash flow was $98 million. The company ended the quarter with $735 million in cash and short-term investments.
  • The following analysis of diluted earnings per share identifies specific items that affect the comparability of results between periods. Reconciliations between the company's GAAP and non-GAAP results for the periods reported are presented in the attached tables and on the company's Investor Relations page at  

  • Three Months Ending Mar 3120112010%GAAP earnings per share



    4.2%Gain on sale of Mass Spectrometry Division(0.14)Non-cash interest expense (FSP APB14-1)


    0.03Business integration and other charges


    0.08Accelerated amortization of debt issuance costs


    0.17Amortization of acquisition related expenses


    0.25Non-GAAP earnings per share$0.85$0.87(2.3%)Business Highlights:

  • Cell Systems division non-GAAP revenue was $238 million in the first quarter, an increase of 11 percent over the same period last year.  Excluding the impact from currency, organic revenue growth was 11 percent year over year.  This growth was a result of strong demand across the portfolio, including double-digit growth in the Beads Based Separation and BioProduction businesses.  
  • Molecular Biology Systems division non-GAAP revenue was $426 million, a decrease of 1 percent over the same period last year.  Excluding the impact from currency and acquisitions, organic revenue for the division declined 3 percent. Strong demand for TaqMan® assay products was offset by the PCR and Molecular Biology Reagents businesses, which both faced difficult year-over-year comparisons.
  • Genetic Systems division non-GAAP revenue was $228 million in the first quarter, a decrease of 4 percent over the same period last year.  Excluding the impact from currency, organic revenue declined 8 percent.  The decline in revenue growth primarily resulted from the delayed shipment of the new 5500 sequencer due to events in Japan, and the impact of year over year comparables on the CE sequencing business.
  • Regional organic growth rates for the quarter compared to the same quarter of the prior year were as follows: the Americas increased 1 percent, Europe 2 percent, and Asia Pacific 7 percent.  Japan declined 16 percent.
  • Revenue from orders transacted through Life Technologies' eCommerce channels grew 25 percent during the quarter. Over 50 percent of all transactions are processed using eCommerce platforms.

  • Company and Technology Highlights:

  • The company launched a number of new consumable products in the quarter, including a new addition to the gold standard TaqMan® product line. The TaqMan® Mutation Detection Assay was developed for clinical researchers to validate and screen for low levels of mutations in cancer-related genes. This new assay is the first of its kind on the market, showing at least 10-fold greater sensitivity than currently available products.
  • The FDA granted 510(k) clearance for StemPro® MSC SFM, a liquid medium designed to efficiently grow human mesenchymal stem cells. StemPro® is the first and only product of its kind to receive clearance from the FDA and has the potential to accelerate the regulatory review process for regenerative medicine studies.
  • The company announced that it has initiated clinical trials leading to a 510(k) submission of a Class I and Class II HLA Sequence-Based Typing solution on the company's Applied Biosystems™ 3500 Dx Genetic Analyzer.  HLA typing is one of the main determinants used in patient-donor compatibility selection for individuals diagnosed with leukemia and other blood cancers.  
  • Furthering our efforts to make genetic sequencing affordable and simple enough for use in all molecular biology labs, the company introduced the Ion OneTouch™ system, a simple, bench-top sample preparation device for use with the Personal Genome Machine.  This automated system reduces the time required to prepare samples to three hours, from 8 to 10 hours using current manual methods.
  • The company announced the opening of a new distribution center in Singapore. This new distribution hub was built to address strong demand for Life Technologies' products in Asia Pacific markets.  Since its inception, the volume of items shipped per day in the region has increased fourfold, dramatically improving order fulfillment time by up to 50 percent. The new Singapore hub puts the company one step closer to its goal of delivering in stock products to customers within 3 to 5 days anywhere in the world.

  • Fiscal Year 2011 OutlookSubject to the risk factors detailed in the Safe Harbor Statement section of this release, the company reiterated its expectations for fiscal year 2011 financial performance. Organic revenues are expected to increase in the mid-single digits.  This level of organic revenue growth is expected to result in approximately $3.80 to $3.95 of non-GAAP earnings per share.   The company will provide further detail on its business outlook during the webcast today.

    Webcast Details The company will discuss its financial and business results as well as its business outlook on its webcast at 4:30 PM ET today.  This webcast will contain forward-looking information.  The webcast will include a discussion of "non-GAAP financial measures" as that term is defined in Regulation G.  For actual results, the most directly comparable GAAP financial measures and information reconciling these non-GAAP financial measures to the company's financial results determined in accordance with GAAP, as well as other material financial and statistical information to be discussed on the webcast will be posted at the company's Investor Relations Web site at The webcast can be accessed through the investor relations page of the Life Technologies' website at A replay of the webcast will be available on the company's website through Tuesday, May 17, 2011.

    About Life Technologies Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and Taqman products.  Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website:

    Safe Harbor Statement Certain statements contained in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and Life Technologies intend that such forward-looking statements be subject to the safe harbor created thereby.  Forward-looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of  the company. Such forward-looking statements include, but are not limited to, statements relating to financial projections, including revenue and pro forma EPS projections; success of acquired businesses, including cost and revenue synergies; development and increased flow of new products; leveraging technology and personnel; advanced opportunities and efficiencies; opportunities for growth; expectations of prospective new standards, new delivery platforms, and new selling specialization and effectiveness; and corporate strategy and performance.  A number of the matters discussed in this presentation that are not historical or current facts deal with potential future circumstances and developments, including future research and development plans. The discussion of such matters is qualified by the inherent risks and uncertainties surrounding future expectations generally and other factors that could cause actual results to differ materially  from future results expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to:  volatility of the financial markets; and the risks that are described from time to time in Life Technologies' reports filed with the SEC.  This presentation speaks only as of its date, and the company disclaims any duty to update the information herein.

    Non-GAAP Measurements

    This press release includes certain financial information which constitutes "non-GAAP financial measures" as defined by the SEC.  The GAAP measures which are most directly comparable to these measures, as well as a reconciliation of these measures with the most directly comparable GAAP measures, can be found at on the Investor Relations portion of the company's website at


    ended March 31, 2011ended March 31, 2010(unaudited)GAAPAdjustmentsNon-GAAPGAAPAdjustmentsNon-GAAPRevenues

    $ 895,893



    $  896,823$ 884,943



    $  887,035Cost of revenues







    281,546Purchased intangibles amortization







    -Gross profit



    72,386605,489Gross margin

    57.9%66.3%60.2%68.3%Operating expenses:Selling, general and administrative







    257,735Research and development







    85,705Business consolidation costs







    -Total operating expenses



    (27,864)343,440Operating income



    100,250262,049Operating margin

    17.7%28.2%18.3%29.5%Interest income



    -1,347Interest expense







    (30,363)Loss on early retirement of debt





    -Gain on divestiture of equity investments




    (9) Other income (expense), net





    2,466Total other income (expense), net



    26,666(26,550)Income from operations before provision for income taxes



    126,916235,499Income tax provision







    (70,552)Net income



    73,440164,947Net loss attributable to non-controlling interests




      10   -

      -   -Net income attributable to controlling interest$   93,687$ 64,248$  157,739$   91,507$
    73,440$  164,947Effective tax rate

    18.7%27.6%15.7%30.0%Add back interest expense for subordinated debt, net of tax

    33335151Numerator for diluted earnings per share$   93,720

    $ 64,248$  157,772$   91,558

    $  164,998Earnings per common share:Basic earnings per share attributable to controlling interest

    Diluted earnings per share attributable to controlling interest

    Weighted average shares used in per share calculation:Basic


    186,266186,266189,834189,834(1)  The Company reports Non-GAAP results which excludes business consolidation costs, amortization of purchase accounting adjustments to deferred revenue, charges for inventory revaluation, amortization of acquired intangibles, depreciation of acquired property, plant, and equipment to provide a supplemental comparison of the results of operations.  In addition, charges related to non-cash interest expense incurred as a result of the retrospective application of the bifurcation requirement between equity and debt prescribed by the Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic of Debt with Conversion and Other Options, costs associated with the early termination of outstanding indebtedness and the impact from the divestiture of our joint venture have been excluded from Non-GAAP results.   (2)  Add back fair value amortization of purchased deferred revenue of $0.9 million and $2.1 million for the three months ended March 31, 2011 and 2010, respectively.   (3)  Adjust for contingent consideration revaluation of $1.9 million, offset with $0.5 million of  purchase accounting related cost of revenues revaluation for the three months ended March 31, 2011.  Add back noncash charges for purchase accounting inventory revaluation cost of $0.2 million for the three months ended March 31, 2010.   (4)  Add back amortization of purchased intangibles.(5)  Add back depreciation of purchase accounting property, plant, and equipment revaluations of $2.1 million and $2.6 million for the three months ended March 31, 2011 and 2010, respectively, and accelerated compensation expense related to business acquisitions of $1.5 million for the three months ended March 31, 2011.   (6)  Add back business consolidation costs.   (7)  Add back charges related to non-cash interest expense as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options of $7.2 million and $11.2 million for the three months ended March 31, 2011 and 2010, respectively. Adjust for imputed finance charge of $1.5 million associated with contingent consideration on business acquisitions for the three months ended March 31, 2011.   (8)  Add back loss on early retirement of debt.   (9)  Adjust for gain on divestiture of equity investments.   (10)  Adjust for gain on impaired security recovery of $6.7 million and gain on foreign currency related to joint venture divestiture of $1.0 million offset by loss on discontinuance of cash flow hedge of $12.9 million and joint venture purchase accounting adjustment of $1.2 million for the three months ended March 31, 2010.(11)  Non-GAAP tax differs from GAAP tax expense primarily because certain acquisition related costs such as: restructuring; amortization of acquired intangibles; depreciation of acquired property, plant, and equipment and; fair market value adjustments to contingent consideration liabilities associated with certain acquisitions. In addition, GAAP net income includes interest expense with related income tax benefits as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options but excluded for Non-GAAP purposes. These deductions produce a GAAP only tax benefit which is added back for Non-GAAP presentation.(12)  Add back noncash charges for purchase accounting inventory revaluations and depreciation of purchase accounting property, plant and equipment revaluations attributable to non-controlling interest, net of tax benefit.   LIFE TECHNOLOGIES CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFor the three monthsended March 31,(in thousands)(unaudited)

    20112010Net income$
    93,579$  91,507Add back amortization and share-based compensation

    98,15593,472Add back depreciation

    30,31731,479Balance sheet changes

    (96,785)(80,655)Other noncash adjustments

    (10,215)(64,980)Net cash provided by operating activities

    115,05170,823Capital expenditures

    (16,576)(30,285)Free cash flow98,47540,538Net cash provided by (used in) investing activities

    (34,287)424,363Net cash used in financing activities

    (194,720)(454,357)Effect of exchange rate changes on cash

    10,6582,022Net increase (decrease) in cash and cash equivalents$ (119,874)$  12,566LIFE TECHNOLOGIES CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETSMarch 31, December 31,(in thousands)

    20112010ASSETS (unaudited) Current assets:Cash and short-term investments

    854,801Trade accounts receivable, net of allowance for doubtful accounts


    340,400323,318Prepaid expenses and other current assets

    198,634280,950Total current assets

    1,893,0372,046,525Long-term assets

    7,382,7607,439,674Total assets

    $ 9,275,797$
    LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Current portion of long-term debt

    347,749Accounts payable, accrued expenses and other current liabilities

    1,005,586798,636Total current liabilities

    1,788,9811,146,385Long-term debt

    2,298,8412,727,624Other long-term liabilities

    802,6001,174,161Stockholders' equity

    4,385,3754,438,029Total liabilities and stockholders' equity

    $ 9,275,797$
    Investor and Financial Contacts
    Eileen Pattinson
    Investor Relations
    (760) 603-7208


    SOURCE Life Technologies Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
    2. RainDance Technologies Appoints Olex Vice President, System Development
    3. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
    4. Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing
    5. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
    6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
    7. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
    8. Anthill Technologies Announces Agreement With Zafgen
    9. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
    10. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
    11. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
    Post Your Comments:
    (Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
    (Date:10/10/2017)... , ... October 10, 2017 , ... ... of 13 prestigious awards honoring scientists who have made outstanding ... a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for ...
    (Date:10/9/2017)... (PRWEB) , ... October 09, ... ... published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s ... the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using ...
    (Date:10/6/2017)... ... October 06, 2017 , ... ... discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). ... Institute. The event is free and open to the public, but registration is ...
    Breaking Biology Technology:
    (Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
    (Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
    (Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
    Breaking Biology News(10 mins):